• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Maxacalcitol Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755164

Maxacalcitol is non-calcemic vitamin D3 analog and ligand of VDR-like receptors. More details

Please Inquire
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Maxacalcitol, Inhibitor
Full Product Name
Maxacalcitol
Product Synonym Names
22-Oxacalcitriol
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
418.61
Solubility
DMSO: 100mg/mL (238.89mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C26H42O4
SMILES
C=C1[C@H](C[C@@H](C/C1=C/C=C2[C@]3([C@@](C)([C@H](CC3)[C@@H](OCCC(C)(O)C)C)CCC/2)[H])O)O
CAS Number
103909-75-7
Target & IC50
Others
In Vitro
Maxacalcitol inhibits parathyroid hormone (PTH) mRNA expression in vitro and in vivo. Maxacalcitol inhibits tumor growth of osteosarcoma in vitro in combination with all-trans retinoic acid. Maxacalcitol shows similar effects to calcitriol in osteoblast-like cells.

Structure of Maxacalcitol, inhibitor

Maxacalcitol Inhibitor – Cat# MBS5755164

Product References and Citations for Maxacalcitol, inhibitor

Barroga, et al. Inhibitory effects of 22-oxa-calcitriol and all-trans retinoic acid on the growth of a canine osteosarcoma derived cell-line in vivo and its pulmonary metastasis in vivo. Res.Vet.Sci. (2000)68 79.
Barroga, et al. Inhibitory effects of 22-oxa-calcitriol and all-trans retinoic acid on the growth of a canine osteosarcoma derived cell-line in vivo and its pulmonary metastasis in vivo. Res.Vet.Sci. (2000)68 79.
Monier-Faugere, et al. 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int. (1999)55 821.
Monier-Faugere, et al. 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int. (1999)55 821.
Inoue K, et al. Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3.Lab Invest. 2012 Aug 27.
Inoue K, et al. Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3.Lab Invest. 2012 Aug 27.
Karashima T, et al. Successful treatment,of Bowen's Disease with Topical Maxacalcitol. Acta Derm Venereol. 2012 Jan 26.
Karashima T, et al. Successful treatment,of Bowen's Disease with Topical Maxacalcitol. Acta Derm Venereol. 2012 Jan 26.

Other Notes

Small volumes of Maxacalcitol, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Maxacalcitol purchase

MBS5755164 is an inhibitor targeting Maxacalcitol.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000